Oncogenic role and therapeutic target of leptin signaling in colorectal cancer
| Autor: | Weiqiang Zhou, Hangjun Gong, Chengyu Luo, Yuwang Tian, Shanchun Guo |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Leptin
Colorectal cancer Angiogenesis Clinical Biochemistry Adipose tissue Adipokine Antineoplastic Agents Biology medicine.disease_cause Risk Factors Cancer stem cell Drug Discovery medicine Animals Humans Molecular Targeted Therapy Obesity Pharmacology medicine.disease Drug Design Immunology Cancer cell Cancer research Molecular Medicine Colorectal Neoplasms Carcinogenesis Signal Transduction |
| Zdroj: | Expert Opinion on Therapeutic Targets. 18:961-971 |
| ISSN: | 1744-7631 1472-8222 |
| DOI: | 10.1517/14728222.2014.926889 |
| Popis: | Obesity is characterized by high secretion of several cytokines from adipose tissue and is a recognized risk factor for many cancers. Among these cytokines, leptin mainly produced by adipose tissue and cancer cells is the most studied adipokine. Leptin is an activator of cell proliferation, an antiapoptotic molecule and inducer of cancer stem cells in many cell types, and its critical roles in obesity-related tumorigenesis are based on its oncogenic, mitogenic, pro-inflammatory and pro-angiogenic actions.These leptin-induced signals and action are critical for their biological effects on energy balance, adiposity, endocrine systems, immunity, angiogenesis as well as oncogenesis. This review focuses on the up-to-date knowledge on the oncogenic role of leptin signaling, clinical significance and specific drug target development in colorectal cancer (CRC). Additionally, leptin-induced angiogenic ability and molecular mechanisms in CRC cells are discussed.Stringent binding affinity of leptin/Ob-R and overexpression of leptin/Ob-R and their targets in cancer cells make it a unique drug target for prevention and treatment of CRC, particularly in obesity colorectal patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|